Uveitis Treatment Market Will Touch A New Level In Upcoming Year – Key Players Forecast 2022 – 2028
Uveitis Treatment Market, By Treatment Type (Antivirals,
Corticosteroids, Monoclonal Antibodies, Antifungal,
Analgesics, Immunosuppressant, Cycloplegic Agents, Antibiotics,), By Disease Type (Anterior
Uveitis, Pan uveitis, Posterior Uveitis), By Distribution Channel (Online
Pharmacies, Hospital Pharmacies, Retail Pharmacies, Drug Stores), and By Region
(North America, Asia Pacific, Latin America, Europe, Middle East & Africa)
- Size, Share, Outlook, and Opportunity Analysis, 2020 – 2027
The Global Uveitis Treatment Market is
estimated to be valued at US$ XX million in XX and is expected to exhibit a
CAGR of XX% during the forecast period, as highlighted in a new report
published by Coherent Market Insights.
Market Overview:
The uvea is the middle layer
of tissue in the wall of the eye. It comprises of the iris, the ciliary body
and the choroid. When one looks at the eye in the mirror, they will see the
white part of the eye and the colored part of the eye.
Competitive
Landscape:
Major players included in
the global uveitis treatment market are Clearside Biomedical, Inc., Allergan,
Inc., Novartis AG, AbbVie Inc., Eyegate Pharmaceuticals, Inc., Valeant
Pharmaceuticals International, Inc., Alimera Sciences Inc., Galapagos, EyePoint
Pharmaceuticals, Inc., Tarsius Pharma and pSivida Corp.
Key
Market Drivers:
High prevalence of uveitis
is expected to propel growth of the global uveitis treatment over the forecast
period. For instance, as per NCBI around 10-15% of total cases in blindness in
United States.
The
increasing prevalence of optical infections and chronic eye disorders across
the globe is expected to be one of the key factors driving the growth of the
market. For instance, the number of people with eye disorders was approximately 2.95 million in 2020.
Covid-19 Impact Analysis:
The
COVID-19 pandemic has impacted the market in the form of disrupted care
patterns, leading to potential disease management changes across a range of
therapeutic areas. The increases cases of pandemic led to shutdowns and delay
in the treatment of other disorders. Which impacted the market. Research predicts
that patients of uveitis can be at huge threat of contracting COVID-19 when
compared with the general population, suffering a more severe course of the
virus.
Key Takeaways:
The
global uveitis market is expected to exhibit a CAGR of XX% during the forecast
period (2019 – 2027), owing to key players in the market aiming on R&D of new
products to expand their product portfolio. For instance, in March 2020,
EyePoint Pharmaceuticals, Inc. declared positive topline 36-month follow-up
data from the second Phase III trial of YUTIQ 0.18 mg three-year micro-insert
for the treatment of chronic non-infectious uveitis affecting the posterior
segment of the eye.
Among
regions North America, Asia Pacific and Europe is anticipated to witness robust
growth in global uveitis treatment market due to rising prevalence of
noninfectious uveitis and rising geriatric population. For instance, as per
UN.gov, there are 703 million
people aged 65 years or over in the world in 2019.
Comments
Post a Comment